About Us

Filament Health is a leading exclusively natural psychedelic drug development company.

We are building a powerful platform to support the treatment of mental health conditions through FDA-approved psychedelic extracts from lab grown and regeneratively harvested plants, produced by our wholly-owned subsidiary, Psilo Scientific.

Play Video

Company Highlights

Leading natural psychedelics IP portfolio
FDA clinical trials using IP-protected natural psychedelic extracts
In-house GMP manufacturing in a Health Canada Dealer’s Licensed facility through our wholly owned subsidiary, Psilo Scientific Ltd.
Management and Board accomplished in botanical extraction, biotech, IP and pharma
Unlocking the vast drug discovery potential of dozens of psychoactive plant species

Management Team

Deep experience in botanical extraction, intellectual property, biotech, pharma, commercialization and capital markets.

Global Experts in Botanical Extraction and Commercialization

Scaled Mazza Innovation from pre-seed to $26M sale to Sensient Technologies in 2018

Developed and commercialized patent-protected, botanical extraction technology at commercial-scale 35,000 sq. ft. GMP facility

Leadership Team
Ben Lightburn
CEO, Director & Co-Founder
Proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies
Lisa Ranken
Chief Operating Officer
Operational and leadership expertise in rapidly growing industries
Ryan Moss
Research and Development
Expert in the field of botanical extraction, purification, standardization
Beatriz Ramos
GMP Specialist
Quality management, regulatory compliance, and attaining third-party certification
Warren Duncan
Chief Financial Officer

Experienced in audit, accounting, capital markets, M&A and equity financing

Previously cannabis-focused investment banker, Cormark Securities, advising on 75+ financing raising > C$6B in proceeds

Wealth of Relevant Experience in Drug Development, FDA Trials and Intellectual Property

Jeff Fellows
Head of Regulatory

30 years of drug development experience leading regulatory development efforts from pre-IND to post-approval

Extensive global clinical trial application filings and health authority interactions

Taran Grey
Director of IP

Extensive patent and trademark portfolio experience in healthcare, technology and other diversified industries

100% pending application to issued patent success rate at Moj.io, Bionic Power & Nextleaf Solutions

Board of Directors and Advisors

Greg Mills
Board Chair

Former Managing Director, Head Global Equities, RBC Capital Markets

Chairman, Sundial Growers Inc.

NEO Exchange, Independent Board member

Maureen O’Connell
Director, Chair of Audit Committee

Certified Public Accountant

Previously EVP, Chief Administrative Officer and Chief Financial Officer at Scholastic

Currently Chairman of Acacia Research and board member of ISACA

Jon Conlin

Partner at Fasken.

Corporate and commercial lawyer specializing in companies in the technology and health sciences sectors including venture capitalists and start-ups

Chris Wagner

Over 25 years of experience in the life sciences industry most recently as CEO and Director of both private and public companies.

Led Prozac and Zyprexa teams at Eli Lilly.

Founder and VP at Aspreva Pharmaceuticals

Josh Woolley, MD/PhD.

Principal Investigator, Advisor

BSc Biology & Psychology, PhD Neuroscience, M.D.

Associate Professor in the Department of Psychiatry and Behavioral Sciences at UCSF; PI and Director of UCSF’s Bonding and Attunement in Neuropsychiatric Disorders Laboratory which is conducting studies on psilocybin and MDMA’s effects on patients with mental illnesses

Tom Kineshanko
Founding Advisor
15 years founding for impact startups and funds in regulated frontier markets. 50+ seed or ICO round startup investments that have gone on to have >$250B cumulative value.


Anna Cordon
Director of Communications
Expert in communications and marketing for global corporations.

Research Partners

University of California, San Francisco

Filament has partnered with UCSF’s Translational Psychedelic Research (TrPR) Program to begin two investigator initiated FDA clinical trials in 2021, led by the Program’s Director, Dr. Joshua Woolley.

As a Board Certified Psychiatrist and experienced psychedelics clinician and researcher, Dr. Woolley will act as Principal Investigator in leading Filament’s unique, protected drug candidates through Phase I and Phase II trials.

The TrPR Program combines innovative basic and clinical research approaches to answer key questions about the mechanisms, safety, and efficacy of psychedelics for specific health conditions. The group’s goal is to accelerate progress towards impactful and accessible psychedelic treatments.

UCSF has a history of working in the translational space, linking laboratory science with patients, and findings with the needs of the community. TrPR is committed to building a collaborative culture and applying open science principles to maximize the integrity and transparency of their work.